Director Clinical Pharmacology in Stevenage

The Department of Clinical Pharmacology Modelling & Simulation Respiratory and Inflammation (CPMS R&I) at GSK is recruiting a director-level Clinical Pharmacologist. This role is based in the UK or US, with remote working or placement at other European GSK sites possible for the right candidate.

Job Purpose

The Director, Clinical Pharmacology sits within the newly established Clinical Pharmacology and Quantitative Medicine (CPQM) organisation, which aims to be a centre of excellence in Model‑Informed Drug Development (MIDD) by integrating clinical pharmacology, digital medicine, translational imaging and mechanistic/systems modelling. You will lead the end‑to‑end application of MIDD across the drug development lifecycle—from first‑in‑human studies through filing and lifecycle management—and provide clinical pharmacology strategy and evidence‑generation input. This is an opportunity to join a highly regarded, high‑impact team with a strong publication track record, reporting directly to the Respiratory, Immunology & Inflammation Research Unit (RIIRU).

Main responsibilities

• Design & Execute Model Informed and Clinical Pharmacology strategies
• Ensure robust ways of working and regulatory ready evidence
• Build cross‑functional partnerships
• External engagement & scientific leadership
• Develop and implement robust MIDD & ClinPharm evidence strategies to de-risk and accelerate RIIRU programs.
• Aim for faster development, optimal dosing and stronger regulatory positioning across respiratory, inflammation, neurodegeneration and emerging areas — and support business development opportunities.
• Draft and review clinical pharmacology regulatory content to support timely approvals and optimal labelling.
• Maintain up to date knowledge of FDA, EMA, CDE, PMDA and ICH expectations and embed regulatory considerations and best practices into study design and MIDD strategies.
• Work closely with CPQM peers (digital medicine, translational imaging, MIDD specialists, mechanistic/systems modelling) and cross functional partners (biology, data science, computational biology, clinical, etc.).
• Maintain strong networks and share best practices in the CPMS community of practice.
• Build strong network key functions such as AI/ML, biomarkers, biostatistics, clinical operations, data science, computational biology and RWE to embed quantitative approaches into decision making at asset level.
• Raise GSK's profile in MIDD, clinical pharmacology, QSP and AI/ML integration through publications, conference presentations and active participation in scientific and regulatory fora to influence method adoption and regulatory dialogue.

Basic Qualifications

• PhD in life sciences or related discipline, MD, or PharmD, with experience in clinical pharmacology, modelling and simulation in pharmaceutical research and development.
• Significant experience in clinical pharmacology, modelling/simulation and drug development to solve practical problems in the pharmaceutical industry.
• Experience in pharmacometrics and their application to clinical questions in drug development.

Preferred Qualifications

• Additional experience in respiratory and immunology would be beneficial.
• Demonstrated experience of collaboration in a multi‑discipline team, using effective communication and taking personal accountability for timely delivery of results.
• Evidenced experience making sound judgement in complex situations and adapting to changing business needs by prioritising multiple tasks.
• Experience working with senior stakeholders in a cross functional environment.
• Track record of implementation of Model‑Informed Drug Discovery and Development (MIDD) approaches to accelerate patient access to novel therapies and to expand therapeutic indications of marketed drugs.
• Drive and learning agility to build knowledge on a drug‑disease system, symptom progression, standard of care, and trial design.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive. We get ahead of disease by preventing and treating it with innovation in specialty medicines and vaccines. We focus on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases to impact health at scale. People and patients around the world count on the medicines and vaccines we make, so we’re committed to creating an environment where our people can thrive and focus on what matters most. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we deliver for patients, shareholders and our people.